WuXi AppTec is the global leader in the pharmaceutical R&D and manufacturing outsourcing industry, with operations spanning the entire chain from drug discovery and preclinical research to clinical and commercial production, serving nearly every drug modality including small molecules, oligonucleotides, peptides, proteins, and cell and gene therapies — an integrated model known in the industry as CRDMO.

Over the past two years, the company has weathered dramatic swings driven by geopolitics, and it is now on a path of robust recovery. Take the most recent development first. In June 2026, the U.S. Department of Defense placed WuXi AppTec on its "Chinese military companies" list under Section 1260H; on November 9, the Defense Department decided to remove the company from the list, citing compliance with a court-approved preliminary injunction ruling. The company promptly issued a voluntary announcement stating that the removal means it will no longer face further adverse effects stemming from the 1260H list. Being wrongly labeled a "military company" had been a sword hanging over WuXi AppTec's head, and that sword has now been lifted.

The geopolitical turmoil was directly reflected in its 2024 financial statements. That year, amid concerns over the U.S. BIOSECURE Act, WuXi AppTec reported revenue of 39.241 billion yuan, down 2.7% year-on-year, and net profit attributable to shareholders of 9.450 billion yuan, down 1.63% year-on-year. It was a rare contraction since the company's listing.

But the core business did not collapse. In 2025, the company's adjusted net profit excluding non-recurring items was 13.241 billion yuan, up 32.56% year-on-year, showing that the main business had returned to a growth trajectory. By the first three quarters of 2026, the recovery had become even more solid.

In the first three quarters of 2026, WuXi AppTec generated operating revenue of 45.537 billion yuan, up 38.59% year-on-year; excluding divested low-growth businesses, continuing operations revenue grew 46.3% year-on-year, indicating the core business grew even faster in real terms. Net profit attributable to shareholders was 19.398 billion yuan, up 60.64% year-on-year, while adjusted net profit excluding non-recurring items was 16.477 billion yuan, up 73.03% year-on-year. The 73% adjusted growth outpacing the 60% attributable growth shows that this round of high growth was genuinely earned by the core business, not propped up by asset sales or one-off gains.

In the third quarter alone, revenue reached 16.64 billion yuan, up 38% year-on-year, and net profit attributable to shareholders was 8.32 billion yuan, up 136.7% year-on-year, slightly beating market expectations.

The growth momentum came mainly from the chemistry business. In the first three quarters, the company's chemistry segment revenue was 39.36 billion yuan, up 51.5% year-on-year. Within that, small-molecule drug R&D and manufacturing outsourcing revenue was 23.58 billion yuan, up 65.6% year-on-year, with 1,089 new molecules added in the first three quarters and a total pipeline of 3,863, including 103 commercial projects and 94 Phase III clinical projects. The peptide and oligonucleotide business, known as TIDES, generated revenue of 11.52 billion yuan, up 46.9% year-on-year, and the company expects full-year growth of about 47%. The number of TIDES clients rose 37% year-on-year and the number of molecules served rose 86% year-on-year, indicating that the strong momentum in this track is continuing. Peptides are the core component of the currently hot GLP-1 weight-loss drugs, and WuXi AppTec is one of the main beneficiaries of this round of peptide capacity expansion.

Testing and biology operations are also keeping pace. In the first three quarters, testing revenue was 3.91 billion yuan, up 32% year-on-year, of which drug safety evaluation revenue grew 40.6%, with revenue related to new molecular modalities accounting for more than 35%. Biology revenue was 2.19 billion yuan, up 12.4% year-on-year, maintaining a leading position in areas such as nucleic acids, conjugates, and multi-specific antibodies.

Profit quality is improving in tandem. In the first three quarters, the company's adjusted non-IFRS gross margin was 54.8%, up 7.8 percentage points year-on-year, and the adjusted non-IFRS net margin attributable to shareholders was 40.4%, up 8.3 percentage points year-on-year. The simultaneous sharp rise in both gross and net margins shows that this round of growth is not just scale expansion but also reflects improved efficiency and product mix. Cash flow is moving in step with profit: adjusted operating cash flow in the first three quarters was 17.28 billion yuan, up 58.9% year-on-year, and the full-year guidance for adjusted free cash flow was raised from 13.5–14.5 billion yuan to 14.5–15.5 billion yuan.

What reassures the market most is the backlog. As of the end of September 2026, WuXi AppTec's backlog for continuing operations reached 76.74 billion yuan, up 36.4% year-on-year, with roughly 27 billion yuan in new orders signed in the third quarter alone. Orders are the hardest leading indicator in the CXO industry, and the 76.7 billion yuan backlog provides visibility for performance over the next year or two.

Based on these fundamentals, the company raised its full-year guidance for two consecutive quarters: overall revenue from 58.5–60.5 billion yuan to 61.0–61.9 billion yuan; continuing operations revenue growth from 35%–39% to 40%–42%; and capital expenditure from 7.5–8.5 billion yuan to 8.0–8.5 billion yuan. Four brokerages — Zhongtai, Tianfeng, Huaxi, and Guojin — all maintained "buy" ratings in their latest notes.

Of course, this recovery is not without points to watch. The shadow of the U.S. BIOSECURE Act has not fully dissipated, and the removal from the 1260H list was based on a court's preliminary injunction, leaving uncertainty going forward. The company's doubling of net profit attributable to shareholders in 2025 included a considerable portion from one-off gains on the sale of part of its stake in the associate WuXi XDC and from business divestitures, and only in 2026 did it return to being purely core-business driven. In addition, the company is divesting some ATU and device testing and clinical trial businesses, and its strategy of focusing on core CRDMO is still underway.

Putting it all together, WuXi AppTec's situation is clear: it withstood the geopolitical shock of 2024, its core business recovered in 2025 and staged a strong recovery in 2026, with adjusted growth, backlog, and gross margin all trending upward, and the blacklist label has been removed. A CXO leader that has emerged from external shocks is proving its resilience with solid orders and profits.

The company is also the global leader in the pharmaceutical R&D and manufacturing outsourcing industry, covering the full chain from drug discovery and preclinical research to clinical and commercial production, and serving nearly all drug modalities under an integrated CRDMO model.

Data sources: WuXi AppTec's 2026 third-quarter report, 2025 annual report, 2023 annual report, and voluntary announcement (Lin 2026-042); segment revenue for chemistry, testing, and biology, backlog, adjusted non-IFRS metrics, and full-year guidance are cited from research reports by Zhongtai, Tianfeng, Huaxi, and Guojin Securities.